BEC SARS-CoV-2 detects UK and South African variants
In collaboration with Pasteur Institute, Bertin Technologies and Enalees validated the test's ability to detect the UK and South African variants of SARS-CoV-2 virus. Now CE-IVD certified, this ultra-rapid diagnostic kit developed in France can therefore be widely used.
The emergence of the more contagious variants of the virus does not slow down the production of the BEC SARS-CoV-2 kit. An in-silico analysis conducted by the Pasteur Institute followed by an experimental validation carried out on January 11, 2021 on the UK variant confirmed the test’s capability in detecting both the UK and South African variants of SARS-CoV-2. This field-deployable test, which offers a rapid & simple diagnostic solution with results in less than 30 minutes, enables quick identification and containment of contamination.
Certified by the French Reference Center (CNR) for respiratory infection viruses several months prior, the BEC SARS-CoV-2 kit is now CE-IVD marked. This European certification thus extends its use beyond France. Karine Bizet, Operational Manager of Healthcare, Biotech & CBRN activities at Bertin Technologies states:
Bertin Technologies succeeded in obtaining the CE-IVD marking of the kit within a very short time, and its use can thus be extended to a greater number of screening facilities.
Developed and manufactured in France, the kit is marketed to businesses and communities. Olivier Varet, Deputy Director of the Life Sciences business line at Bertin Technologies, emphasizes:
Bertin Technologies has reached a production rate on the BEC SARS-CoV-2 kit that meets the current demand of our customers. This production, carried out in the Paris region, which relies on the skills of our internal laboratory and the support of Enalees, responds to the major challenge of the availability of efficient and rapid screening kits.
Since the BEC SARS-CoV-2 test is designed in part with procedural knowledge of Enalees, Laurent Thiery, President of Enalees adds:
A high-speed manufacturing platform for rapid PCR tests developed with the support of the Paris region will soon allow Enalees to further aid the production of these tests.